unbuzzd beverage heads to Puerto Rico via FUSION partnershi

TORONTO - Quantum BioPharma Ltd. (NASDAQ: QNTM), a small-cap biotech company with a market capitalization of $22 million that according to InvestingPro analysis is currently undervalued, has announced that its licensee, Celly Nutrition Corporation, is launching the anti-hangover beverage unbuzzd in Puerto Rico through a distribution partnership with FUSION Distribution Group. FUSION, a prominent distributor of health-conscious products in Puerto Rico and the Caribbean, will add unbuzzd to its portfolio, making it available in various retail and hospitality venues across the region.

unbuzzd, which claims to accelerate alcohol metabolism and reduce hangover symptoms, is scientifically backed by a double-blind placebo-controlled crossover study. The beverage will be sold in single-use powder stick packs and distributed through FUSION’s network, which includes major retailers like Walmart and Costco, as well as pharmacies and food service operations.

John Duffy, CEO of Celly Nutrition, expressed that the launch in Puerto Rico is a key step in making unbuzzd more accessible to consumers. Eduardo Santacana, CEO of FUSION, also conveyed excitement about introducing the product to the Caribbean market, aiming to make it readily available to consumers.

Celly Nutrition, a non-trading public issuer, developed unbuzzd with a proprietary blend of vitamins, minerals, and herbs designed to help the body process alcohol faster. The product is currently available in different pack sizes on amazon.com and unbuzzd.com.

Quantum BioPharma, which invented unbuzzd, retains a 25.71% ownership in Celly Nutrition as of June 30, 2024, and is entitled to royalty payments from unbuzzd sales until reaching a total of $250 million. Afterward, the royalty rate decreases, but the company maintains rights to develop similar products for pharmaceutical and medical uses. InvestingPro data shows the company maintains a healthy balance sheet with more cash than debt, though it’s currently experiencing significant cash burn.

This expansion news is based on a press release statement and involves forward-looking information that may be subject to risks and uncertainties. Quantum BioPharma has made no further comments on the potential impact of this partnership on its financial performance or market position. The stock has shown strong momentum recently, gaining 105% over the past six months despite a challenging year. InvestingPro subscribers have access to 8 additional key insights about QNTM’s financial health and growth prospects.

In other recent news, Quantum BioPharma Ltd. has completed a $5 million funding round, earmarked to advance its research and development efforts and sustain operations until at least the first quarter of 2027. The company has also reported progress in clinical trials, including favorable results from the Phase 1 trial of its Multiple Sclerosis drug, Lucid-21-302, and the completion of a trial for the dietary supplement unbuzzd, which showed promising results in reducing Blood Alcohol Concentration. Financially, Quantum BioPharma revealed a strengthened balance sheet with cash and cash equivalents totaling $12.1 million USD as of the end of 2024, alongside a reduction in net loss by 18%. The company has diversified its investments by purchasing an additional $1 million in cryptocurrencies, doubling its holdings to $2 million.

In corporate developments, Quantum BioPharma appointed Terry Lynch to its board of directors, bringing significant experience in fundraising and biotech investments. Furthermore, Quantum BioPharma’s investment in Celly Nutrition Corp., which is preparing for an IPO to raise $10 million USD, highlights its strategic interest in the beverage market. Celly Nutrition’s product, unbuzzd, is designed to mitigate hangover symptoms and is set to expand its market presence. Quantum BioPharma’s strategic moves and financial maneuvers reflect its ongoing commitment to innovation and market expansion in the biopharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.